Lung Therapeutics, Inc. Raises $14.3 Million Series B Financing to Treat Unmet Needs in Lung Disease and Fibrosis
Financing will support further development of the Company’s LTI-03 transformative drug technology and the current multi-site clinical trial of orphan drug LTI-01.